TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15725048

Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg once daily for 3 days
Number of subjects: 322

Group type: COMPARATOR
Intervention: Clarithromycin 500 mg twice daily for 10 days
Number of subjects: 322
Study: 12119598

Group type: EXPERIMENTAL
Intervention: Kangaroo care (KC)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control
Number of subjects: 34
Study: 10461807

Group type: EXPERIMENTAL
Intervention: Active avoidance and behavioral control during threat/performance trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perceived control over an aversive event (loud noise)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Behavioral control
Number of subjects: 0
Study: 7757984

Group type: EXPERIMENTAL
Intervention: Cisplatin-based chemotherapy (cisplatin 80 mg/m2 i.v. on day 1, vindesine 3 mg/m2 i.v. on days 1 and 8, with or without mitomycin 8 mg/m2 i.v. on day 1)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Cisplatin-based chemotherapy
Number of subjects: 21
Study: 2405239

Group type: EXPERIMENTAL
Intervention: Teacher-led programme
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Peer-led programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Perceived influence of advertising
Number of subjects: 0
Study: 7216093

Group type: EXPERIMENTAL
Intervention: Slow release iron preparations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quick release iron preparations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All oral iron preparations
Number of subjects: 0
Study: 31586587

Group type: EXPERIMENTAL
Intervention: Baicalein at 0.01% (w/v)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Baicalein at 0.05% (w/v)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Baicalein at 0.1% (w/v)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (0% baicalein)
Number of subjects: 60
Study: 28800972

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 24347521

Group type: EXPERIMENTAL
Intervention: Internet-based program with e-mail support from an urotherapist (n=124)
Number of subjects: 250

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 250

Group type: COMPARATOR
Intervention: Postal program (n=126)
Number of subjects: 250
Study: 23635552

Group type: EXPERIMENTAL
Intervention: Sunitinib 25 mg orally daily and rapamycin 2 mg orally daily (4 weeks on, 2 weeks off)
Number of subjects: 19
Study: 21552662

Group type: EXPERIMENTAL
Intervention: High-frequency neuromuscular electrical stimulation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 30
Study: 19146684

Group type: EXPERIMENTAL
Intervention: Total laparoscopic hysterectomy (TLH + BSO)
Number of subjects: 275

Group type: COMPARATOR
Intervention: Total abdominal hysterectomy (TAH + BSO)
Number of subjects: 275
Study: 15990827

Group type: EXPERIMENTAL
Intervention: Intravenous N-acetylcysteine (NAC) at a loading dose of 70 mg/kg 2 hours before and 35 mg/kg at 4-hour intervals for a total of 24 hours after the procedure
Number of subjects: 256

Group type: COMPARATOR
Intervention: Normal saline solution (placebo)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Intravenous N-acetylcysteine (NAC)
Number of subjects: 256
Study: 12566660

Group type: EXPERIMENTAL
Intervention: K/DOQI recommended targets for adequacy of dialysis (weekly Kt/V 2 + creatinine clearance 50‐60 l/1.73 m(2))
Number of subjects: 0

Group type: COMPARATOR
Intervention: Higher than recommended small solute clearance targets
Number of subjects: 0
Study: 10628101

Group type: EXPERIMENTAL
Intervention: Telephone intervention for preventive health care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Telephone intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomized trial
Number of subjects: 0
Study: 8931970

Group type: EXPERIMENTAL
Intervention: Intramuscular diclofenac 75 mg
Number of subjects: 83

Group type: COMPARATOR
Intervention: Intravenous indomethacin 50 mg
Number of subjects: 83
Study: 1868973

Group type: EXPERIMENTAL
Intervention: 40 mg omeprazole, administered intravenously 4 times a day
Number of subjects: 9

Group type: COMPARATOR
Intervention: Baseline period
Number of subjects: 9
Study: 6354530

Group type: EXPERIMENTAL
Intervention: Captopril (50 mg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Captopril (50 mg) + Naloxone (0.2 mg/kg i.v.)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 30560316

Group type: EXPERIMENTAL
Intervention: Active LLTS (20 Hz, 1 mA below discomfort threshold)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Active LLTS
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 24
Study: 28893244

Group type: EXPERIMENTAL
Intervention: Omarigliptin 25 mg once weekly (q.w.)
Number of subjects: 4202

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4202
Study: 26802156

Group type: EXPERIMENTAL
Intervention: Combination of cediranib 30 mg once daily and saracatinib 175 mg once daily (CS)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Cediranib 45 mg once daily and placebo (C)
Number of subjects: 138
Study: 25095833

Group type: EXPERIMENTAL
Intervention: Clearfl Protect Bond (self‐etch containing fluoride and MDPB adhesive, CB)
Number of subjects: 10

Group type: COMPARATOR
Intervention: All‐Bond SE(TM) (self‐etch, fluoride/MDPB free adhesive, AB)
Number of subjects: 10
Study: 22334456

Group type: EXPERIMENTAL
Intervention: sorafenib at a dose of 400 mg twice daily
Number of subjects: 80

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: sorafenib
Number of subjects: 80
Study: 19103363

Group type: EXPERIMENTAL
Intervention: Low- to mid-potency topical steroids (short-term therapy for 2-4 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical calcipotriene (calcipotriol), pimecrolimus, or tacrolimus (long-term therapy)
Number of subjects: 0
Study: 17556352

Group type: EXPERIMENTAL
Intervention: Sevoflurane (Group S, n = 123)
Number of subjects: 237

Group type: COMPARATOR
Intervention: Desflurane (Group D, n = 114)
Number of subjects: 237
Study: 15792196

Group type: EXPERIMENTAL
Intervention: 50 Hz magnetic field exposure (96 mT)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Reactive hyperemia
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Hyperventilation (10 deep breaths)
Number of subjects: 10
Study: 11965415

Group type: EXPERIMENTAL
Intervention: Parkinsonian patients (P)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Non-parkinsonian patients (NP)
Number of subjects: 40
Study: 9798025

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (500 mg twice a day for 14 days)
Number of subjects: 376

Group type: COMPARATOR
Intervention: Clarithromycin (500 mg twice a day for 14 days)
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 376

Group type: COMPARATOR
Intervention: Clarithromycin
Number of subjects: 376
Study: 7697951

Group type: EXPERIMENTAL
Intervention: MK-0591 (250 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 2507831

Group type: EXPERIMENTAL
Intervention: Special precautions (topical lidocaine by inhalation, bronchoscope through endotracheal tube)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Routine BAL procedure
Number of subjects: 20
Study: 322635

Group type: EXPERIMENTAL
Intervention: Lithium carbonate (mean 0.91 mEq/liter)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Ethanol (1.32 ml/kg of body weight)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Lithium carbonate
Number of subjects: 23
Study: 30704524

Group type: EXPERIMENTAL
Intervention: PTEN-low and reduced expression of hsa-miR-4324, hsa-miR-125b, hsa-miR-381, hsa-miR-145, and has-miR136
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PTEN-low/miR-low subgroup
Number of subjects: 0

Group type: COMPARATOR
Intervention: Connectivity mapping
Number of subjects: 0
Study: 28598894

Group type: EXPERIMENTAL
Intervention: 15° left tilt of the surgical table (tilt group)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Supine horizontal position (supine group)
Number of subjects: 100
Study: 25655678

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes
Number of subjects: 559

Group type: COMPARATOR
Intervention: No diabetes
Number of subjects: 559

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes (in males)
Number of subjects: 559

Group type: COMPARATOR
Intervention: Other metabolic factors and MetS
Number of subjects: 559
Study: 23942586

Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MedDiet)
Number of subjects: 7018

Group type: COMPARATOR
Intervention: Control group (no MedDiet)
Number of subjects: 7018
Study: 21574208

Group type: EXPERIMENTAL
Intervention: Minimal Intervention (MI)
Number of subjects: 467

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 467

Group type: EXPERIMENTAL
Intervention: Bupropion (BUP)
Number of subjects: 467

Group type: EXPERIMENTAL
Intervention: Nicotine Replacements (NRT)
Number of subjects: 467
Study: 19185173

Group type: EXPERIMENTAL
Intervention: Minimized cardiopulmonary bypass circuit
Number of subjects: 199

Group type: COMPARATOR
Intervention: Standard cardiopulmonary bypass circuit
Number of subjects: 199
Study: 16430312

Group type: EXPERIMENTAL
Intervention: Ximelagatran 48mg with food
Number of subjects: 24

Group type: COMPARATOR
Intervention: Ximelagatran 48mg without food
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Repeated dosing of ximelagatran 48mg every 12 hours for 5 days
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Single dose of ximelagatran 48mg on day 6
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Repeated dosing of ximelagatran
Number of subjects: 24
Study: 14667010

Group type: EXPERIMENTAL
Intervention: Resin modified glass ionomer (Material A)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Conventional glass-ionomer cement (Material B)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no fissure sealant, received oral health education)
Number of subjects: 100
Study: 10945014

Group type: EXPERIMENTAL
Intervention: Vinorelbine plus AC (adriamycin + cyclophosphamide)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vinorelbine (monotherapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vinorelbine plus 5-fluorouracil
Number of subjects: 0
Study: 8857472

Group type: EXPERIMENTAL
Intervention: Descriptions under no time constraints
Number of subjects: 0

Group type: COMPARATOR
Intervention: Descriptions under time pressure
Number of subjects: 0
Study: 1582503

Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen treatment
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: AR category (median value used as cut-off)
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: AR content (greater than or equal to 10 pmol/g)
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Improved AR assay
Number of subjects: 224
Study: 6394217

Group type: EXPERIMENTAL
Intervention: Augmentin
Number of subjects: 64

Group type: COMPARATOR
Intervention: Cefaclor
Number of subjects: 64
Study: 30937964

Group type: EXPERIMENTAL
Intervention: Atopic mothers
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Cord blood samples
Number of subjects: 163

Group type: COMPARATOR
Intervention: Male newborns
Number of subjects: 163

Group type: COMPARATOR
Intervention: Maternal factors (age, pregnancy variables, allergens exposure, smoking, maternal IgE)
Number of subjects: 163
Study: 30271133

Group type: EXPERIMENTAL
Intervention: Screening for ADRD using the Memory Impairment Screen
Number of subjects: 1723

Group type: EXPERIMENTAL
Intervention: Age, sex, and education of patients
Number of subjects: 1723
Study: 27872111

Group type: EXPERIMENTAL
Intervention: Ultrasound tailored treatment (disclosure of the ultrasound diagnosis)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Usual care (non-disclosure of the ultrasound diagnosis)
Number of subjects: 129
Study: 23212894

Group type: EXPERIMENTAL
Intervention: Manual-based group program for mental health improvement
Number of subjects: 337
Study: 22221670

Group type: EXPERIMENTAL
Intervention: Improvisational music therapy (one session per week)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Improvisational music therapy (three sessions per week)
Number of subjects: 235

Group type: COMPARATOR
Intervention: Parent counselling (three sessions at 0, 2, and 5 months)
Number of subjects: 235
Study: 19781847

Group type: EXPERIMENTAL
Intervention: Vardenafil 5 mg/d at bedtime
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 17959922

Group type: EXPERIMENTAL
Intervention: Stanford V regimen
Number of subjects: 25

Group type: COMPARATOR
Intervention: ABVD regimen
Number of subjects: 25
Study: 15868015

Group type: EXPERIMENTAL
Intervention: Training intervention for clinic staff (18-hour experiential, participatory in-service training programme)
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Control group (usual DOTS strategy)
Number of subjects: 1200
Study: 12501132

Group type: EXPERIMENTAL
Intervention: Selenium (200 microg/day)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 186
Study: 11682428

Group type: EXPERIMENTAL
Intervention: ProSeal laryngeal mask airway
Number of subjects: 0

Group type: COMPARATOR
Intervention: Classic laryngeal mask airway
Number of subjects: 0
Study: 9141524

Group type: EXPERIMENTAL
Intervention: 10 mg cetrorelix for 5 days followed by 2 mg/day
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 10 mg cetrorelix for 5 days followed by 2 x 1 mg/day
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 10 mg cetrorelix for 5 days followed by 1 mg/day
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo injections for 3 weeks
Number of subjects: 16
Study: 8246770

Group type: EXPERIMENTAL
Intervention: 25 g galactose
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 25 g galactose + 25 g glucose
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 50 g lactose
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 50 g glucose (reference)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Water only (control meal)
Number of subjects: 8
Study: 3658567

Group type: EXPERIMENTAL
Intervention: Sustained release methylphenidate (Ritalin [SR‐20])
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Standard methylphenidate (Ritalin, 10 mg, administered twice daily)
Number of subjects: 22
Study: 29914159

Group type: EXPERIMENTAL
Intervention: Trapezoidal flap (Group I)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Modified triangular flap (Group II)
Number of subjects: 15
Study: 27294433

Group type: EXPERIMENTAL
Intervention: OFD with PRF
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: OFD with PRF + 1.2% ATV
Number of subjects: 96

Group type: COMPARATOR
Intervention: OFD alone
Number of subjects: 96
Study: 25169073

Group type: EXPERIMENTAL
Intervention: Community-scheduled screening and treatment (CSST) using community health workers (CHW)
Number of subjects: 0
Study: 23384442

Group type: EXPERIMENTAL
Intervention: Motivational Intervention with typical community service (MI)
Number of subjects: 992

Group type: EXPERIMENTAL
Intervention: Motivational Intervention with exposure to a hospital trauma center (MI-H)
Number of subjects: 992

Group type: COMPARATOR
Intervention: Enhanced prototypic community service (CS)
Number of subjects: 992

Group type: EXPERIMENTAL
Intervention: Combined MI groups (MI and MI-H)
Number of subjects: 992
Study: 20606123

Group type: EXPERIMENTAL
Intervention: B-type natriuretic peptide signal peptide (BNPsp)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: BNPsp
Number of subjects: 25
Study: 18345471

Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy (IPT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Short-term Psychodynamic Psychotherapy (STPP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Client Centred Psychotherapy (CCPT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of specific psychotherapies with antidepressive medication
Number of subjects: 0
Study: 16888465

Group type: EXPERIMENTAL
Intervention: Self-adapted mouthguard (SA)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Custom-made mouthguard (CM)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Normal condition
Number of subjects: 19
Study: 14524397

Group type: EXPERIMENTAL
Intervention: Nonpharmacologic methods of pain relief (labor support, intradermal water blocks, warm water baths)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased availability of nonpharmacologic methods
Number of subjects: 0
Study: 10947304

Group type: EXPERIMENTAL
Intervention: Misoprostol plus any NSAID therapy
Number of subjects: 8843

Group type: COMPARATOR
Intervention: Placebo plus any NSAID therapy
Number of subjects: 8843
Study: 8869390

Group type: EXPERIMENTAL
Intervention: Cabergoline
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 1727091

Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 568
Study: 29889917

Group type: EXPERIMENTAL
Intervention: Presaturated cord
Number of subjects: 50

Group type: COMPARATOR
Intervention: Diode laser
Number of subjects: 50

Group type: COMPARATOR
Intervention: Nd:YAG laser
Number of subjects: 50

Group type: COMPARATOR
Intervention: Er:YAG laser
Number of subjects: 50
Study: 26562107

Group type: EXPERIMENTAL
Intervention: Home visiting program (Healthy Families Massachusetts)
Number of subjects: 704
Study: 25031330

Group type: EXPERIMENTAL
Intervention: Maternal urinary iodine concentration (UIC) < 1.0 mg/L
Number of subjects: 1617
Study: 22688337

Group type: EXPERIMENTAL
Intervention: Insulin aspart (0.1 and 0.2 units/kg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 19926367

Group type: EXPERIMENTAL
Intervention: Calorie restriction (approximately 2 MJ)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Exercise (net deficit of approximately 2 MJ)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Calorie restriction-plus-exercise (total energy deficit of approximately 2 MJ)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (rest)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 6
Study: 18840867

Group type: EXPERIMENTAL
Intervention: Face-to-face training
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: Self-taught package
Number of subjects: 607

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 607
Study: 17068980

Group type: EXPERIMENTAL
Intervention: Behavioral interventions (including unmodified extinction, extinction with parental presence, preventive parent education)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Graduated extinction, bedtime fading/positive routines, scheduled awakenings
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Behavioral treatments
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standardized bedtime routines and positive reinforcement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combination of behavioral therapies
Number of subjects: 0
Study: 12920525

Group type: EXPERIMENTAL
Intervention: Carbon dioxide (CO2) detection
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Volatile organic compound (VOC) localization
Number of subjects: 60
Study: 10678261

Group type: EXPERIMENTAL
Intervention: Sibutramine 15 mg by mouth once per day
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 9256128

Group type: EXPERIMENTAL
Intervention: Amifostine (740 or 910 mg/m2) followed by cisplatin (120 mg/m2) and vinblastine (5 mg/m2)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Amifostine (340 mg/m2 4 days a week for 5 weeks, or 200 mg/m2 5 days a week for 6 weeks) before radiation therapy
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Amifostine
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Vinblastine
Number of subjects: 26
Study: 8150921

Group type: EXPERIMENTAL
Intervention: Intracytoplasmic single sperm injection (ICSI)
Number of subjects: 23
Study: 3539714

Group type: EXPERIMENTAL
Intervention: 35% branched chain amino acids
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 53% branched chain amino acids
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 100% branched chain amino acids
Number of subjects: 37

Group type: COMPARATOR
Intervention: 0% branched chain amino acids
Number of subjects: 37

Group type: COMPARATOR
Intervention: 16% branched chain amino acids
Number of subjects: 37
Study: 28929356

Group type: EXPERIMENTAL
Intervention: High AAC score in elderly patients (Group A)
Number of subjects: 0

Group type: COMPARATOR
Intervention: BMI ≥ 25 in patients with CR-POPF (Group C)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Male gender in patients with CR-POPF (Group C)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Soft pancreatic parenchyma in patients with CR-POPF (Group C)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Absence of MPD dilatation in patients with CR-POPF (Group C)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BMI ≥ 25 in patients with CR-POPF (Group E)
Number of subjects: 0
Study: 26861782

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24813581

Group type: EXPERIMENTAL
Intervention: Forearm blood pressure measurement
Number of subjects: 44

Group type: COMPARATOR
Intervention: Upper arm blood pressure measurement
Number of subjects: 44

Group type: COMPARATOR
Intervention: Upper arm/forearm systolic measures
Number of subjects: 44
Study: 22678515

Group type: EXPERIMENTAL
Intervention: Coopdech videolaryngoscope (VLP-100)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Airway Scope (AWS)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 50

Group type: COMPARATOR
Intervention: All devices
Number of subjects: 50
Study: 19818442

Group type: EXPERIMENTAL
Intervention: High-Monounsaturated Fatty Acids (HMUFA) diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-Saturated Fatty Acids (HSFA) diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-Fat High-Complex Carbohydrate (LFHCC) diet (placebo)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-Fat High-Complex Carbohydrate (LFHCC) diet (n-3 PUFA)
Number of subjects: 0
Study: 18359651

Group type: EXPERIMENTAL
Intervention: 2% pirenzepine ophthalmic gel
Number of subjects: 174

Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 174